DK1993357T3 - Formuleringer af en tight junction effektor - Google Patents
Formuleringer af en tight junction effektorInfo
- Publication number
- DK1993357T3 DK1993357T3 DK07750332.4T DK07750332T DK1993357T3 DK 1993357 T3 DK1993357 T3 DK 1993357T3 DK 07750332 T DK07750332 T DK 07750332T DK 1993357 T3 DK1993357 T3 DK 1993357T3
- Authority
- DK
- Denmark
- Prior art keywords
- formulations
- tight junction
- junction effector
- effector
- tight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/009—Sachets, pouches characterised by the material or function of the envelope
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77145406P | 2006-02-09 | 2006-02-09 | |
PCT/US2007/003486 WO2007095092A2 (en) | 2006-02-09 | 2007-02-09 | Formulations for a tight junction effector |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1993357T3 true DK1993357T3 (da) | 2014-04-22 |
Family
ID=38372020
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07750332.4T DK1993357T3 (da) | 2006-02-09 | 2007-02-09 | Formuleringer af en tight junction effektor |
DK14150323.5T DK2777695T3 (da) | 2006-02-09 | 2007-02-09 | Formuleringer til en tight-junction-effektor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14150323.5T DK2777695T3 (da) | 2006-02-09 | 2007-02-09 | Formuleringer til en tight-junction-effektor |
Country Status (20)
Country | Link |
---|---|
US (5) | US9265811B2 (da) |
EP (2) | EP1993357B1 (da) |
JP (1) | JP5398268B2 (da) |
KR (1) | KR101393652B1 (da) |
CN (2) | CN101420850A (da) |
AR (1) | AR060103A1 (da) |
AU (1) | AU2007215304B2 (da) |
BR (1) | BRPI0707616A2 (da) |
CA (2) | CA2838399C (da) |
DK (2) | DK1993357T3 (da) |
ES (2) | ES2459018T3 (da) |
HK (2) | HK1126088A1 (da) |
IL (2) | IL193344A (da) |
MX (1) | MX2008010221A (da) |
NZ (1) | NZ570427A (da) |
PH (1) | PH12012501912B1 (da) |
RU (1) | RU2008136208A (da) |
TW (1) | TWI478721B (da) |
WO (1) | WO2007095092A2 (da) |
ZA (1) | ZA200807111B (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE438405T1 (de) * | 2000-05-19 | 2009-08-15 | Univ Maryland | Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes |
ZA200807111B (en) | 2006-02-09 | 2009-11-25 | Alba Therapeutics Corp | Formulations for a tight junction effector |
WO2008043107A2 (en) * | 2006-10-06 | 2008-04-10 | Alba Therapeutics Corporation | Use of tight junction antagonists to treat inflammatory bowel disease |
WO2008052185A2 (en) | 2006-10-26 | 2008-05-02 | Alba Therapeutics Corp | Materials and methods for the treatment of celiac disease |
EP2091551B1 (en) * | 2006-11-03 | 2020-01-15 | Alba Therapeutics Corporation | Method of treating asthma |
US20090088404A1 (en) * | 2007-01-31 | 2009-04-02 | Methylation Sciences International Srl | Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
JP2010523555A (ja) | 2007-04-04 | 2010-07-15 | シグモイド・ファーマ・リミテッド | 「経口医薬組成物」 |
US20110201543A1 (en) * | 2007-06-29 | 2011-08-18 | Blake Paterson | Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress |
US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
ES2343499B1 (es) * | 2007-12-24 | 2011-06-10 | Consejo Superior De Investigaciones Cientificas | Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. |
US8957032B2 (en) | 2008-05-06 | 2015-02-17 | Alba Therapeutics Corporation | Inhibition of gliadin peptides |
CA2762179A1 (en) | 2009-05-18 | 2010-11-25 | Sigmoid Pharma Limited | Composition comprising oil drops |
US20110027342A1 (en) * | 2009-07-28 | 2011-02-03 | Msi Methylation Sciences, Inc. | S-adenosylmethionine formulations with enhanced bioavailability |
US8329208B2 (en) | 2009-07-28 | 2012-12-11 | Methylation Sciences International Srl | Pharmacokinetics of S-adenosylmethionine formulations |
WO2012044960A1 (en) * | 2010-10-01 | 2012-04-05 | The Ramaekers Family Trust | Enhancement of immune response by transfer factor |
GB201020032D0 (en) | 2010-11-25 | 2011-01-12 | Sigmoid Pharma Ltd | Composition |
BR112014024159A2 (pt) | 2012-03-29 | 2017-06-20 | Therabiome Llc | Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice. |
GB201212010D0 (en) | 2012-07-05 | 2012-08-22 | Sigmoid Pharma Ltd | Formulations |
US9907755B2 (en) | 2013-03-14 | 2018-03-06 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
GB201319791D0 (en) | 2013-11-08 | 2013-12-25 | Sigmoid Pharma Ltd | Formulations |
WO2015154010A1 (en) | 2014-04-04 | 2015-10-08 | Perrow Wendy | Methods of treating celiac disease with larazotide |
AU2015341695B2 (en) | 2014-11-07 | 2021-07-08 | Sublimity Therapeutics Limited | Compositions comprising cyclosporin |
US10993947B2 (en) * | 2016-05-18 | 2021-05-04 | Torqur | Treatment of skin lesions |
RU2765868C2 (ru) * | 2016-05-18 | 2022-02-04 | Торкур АГ | Лечение неврологических расстройств |
WO2018115984A1 (en) | 2016-12-19 | 2018-06-28 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation |
EP3579862A4 (en) | 2017-02-10 | 2020-12-23 | 9 Meters Biopharma, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE ASSOCIATED WITH PERMEABILITY OF INTESTINAL EPITHELIUM |
ES2938609T3 (es) | 2017-09-20 | 2023-04-13 | Tillotts Pharma Ag | Preparación de formas farmacéuticas sólidas que comprenden anticuerpos mediante estratificación de solución/suspensión |
EP3755315A4 (en) | 2018-02-23 | 2022-01-05 | 9 Meters Biopharma, Inc. | COMPOUNDS AND METHODS OF TREATING THE PERMEABILITY OF SEALED CONNECTIONS |
WO2019165345A1 (en) * | 2018-02-23 | 2019-08-29 | Innovate Biopharmaceuticals, Inc. | Compositions and methods for treating or preventing intestinal paracellular permeability |
US20210361734A1 (en) | 2018-03-19 | 2021-11-25 | 9 Meters Biopharma, Inc. | Compositions and methods for potentiating immune checkpoint inhibitor therapy |
WO2020227341A1 (en) * | 2019-05-06 | 2020-11-12 | 9 Meters Biopharma, Inc. | Compositions and methods for treating sjogren's syndrome |
WO2021034629A1 (en) * | 2019-08-16 | 2021-02-25 | 9 Meters Biopharma, Inc. | Larazotide formulations |
IL300660A (en) * | 2020-08-18 | 2023-04-01 | Cephalon Llc | Antibodies against PAR-2 and methods of using them |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5643602A (en) | 1989-11-22 | 1997-07-01 | Astra Aktiebolag | Oral composition for the treatment of inflammatory bowel disease |
US5395750A (en) | 1992-02-28 | 1995-03-07 | Hoffmann-La Roche Inc. | Methods for producing proteins which bind to predetermined antigens |
AU5615594A (en) | 1992-11-13 | 1994-06-08 | Cancer Research Fund Of Contra Costa | Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods |
JP2996864B2 (ja) | 1994-03-30 | 2000-01-11 | 寳酒造株式会社 | 抗体可変領域dna |
US20020094346A1 (en) * | 1995-05-17 | 2002-07-18 | M. D. Henry C. Lin | Method and compositions for improving digestion and absorption in the small intestine |
US5827534A (en) | 1995-05-24 | 1998-10-27 | University Of Maryland At Baltimore | Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery |
US5665389A (en) | 1995-05-24 | 1997-09-09 | University Of Maryland At Baltimore | Oral dosage composition for intestinal delivery and method of treating diabetes |
CA2249742A1 (en) | 1996-03-15 | 1997-09-18 | Steven G. Reed | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
US5908825A (en) | 1997-01-09 | 1999-06-01 | University Of Maryland At Baltimore | Dosage composition for nasal delivery and method of use of the same |
US5864014A (en) | 1997-02-20 | 1999-01-26 | University Of Maryland At Baltimore | Zonula occludens toxin receptor |
US5912323A (en) | 1997-02-20 | 1999-06-15 | University Of Maryland, Baltimore | Zonula occludens toxin receptors |
US5945510A (en) | 1997-05-21 | 1999-08-31 | University Of Maryland, Baltimore | Substantially pure zonulin, a physiological modulator of mammalian tight junctions |
US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
US6458925B1 (en) | 1998-08-03 | 2002-10-01 | University Of Maryland, Baltimore | Peptide antagonists of zonulin and methods for use of the same |
US6733762B1 (en) | 1998-09-14 | 2004-05-11 | University Of Maryland, Baltimore | Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner |
DE69939748D1 (de) * | 1998-11-02 | 2008-11-27 | Elan Pharma Int Ltd | Multipartikuläre zusammensetzung von methylphenidat mit modifizierter freisetzung |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
ATE438405T1 (de) * | 2000-05-19 | 2009-08-15 | Univ Maryland | Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes |
WO2002060415A1 (de) * | 2001-01-31 | 2002-08-08 | Röhm GmbH & Co. KG | Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen |
EP1519717B1 (en) * | 2002-07-05 | 2010-09-29 | Temrel Limited | Controlled release composition |
DE10332160A1 (de) * | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
KR20080056318A (ko) | 2003-07-15 | 2008-06-20 | 유니버시티 오브 메릴랜드, 볼티모어 | Zot 및 조눌린에 대한 수용체의 작용제 폴리펩티드 |
TW200539903A (en) | 2004-03-12 | 2005-12-16 | Smithkline Beecham Plc | Pharmaceutical formulations |
EP1929298A4 (en) | 2005-05-13 | 2008-11-05 | Univ Maryland | METHOD FOR ASSESSING THE EFFECTIVENESS OF A TREATMENT PLAN |
ZA200807111B (en) * | 2006-02-09 | 2009-11-25 | Alba Therapeutics Corp | Formulations for a tight junction effector |
WO2008043107A2 (en) | 2006-10-06 | 2008-04-10 | Alba Therapeutics Corporation | Use of tight junction antagonists to treat inflammatory bowel disease |
WO2008052185A2 (en) | 2006-10-26 | 2008-05-02 | Alba Therapeutics Corp | Materials and methods for the treatment of celiac disease |
-
2007
- 2007-02-09 ZA ZA200807111A patent/ZA200807111B/xx unknown
- 2007-02-09 NZ NZ570427A patent/NZ570427A/en not_active IP Right Cessation
- 2007-02-09 CA CA2838399A patent/CA2838399C/en active Active
- 2007-02-09 JP JP2008554375A patent/JP5398268B2/ja not_active Expired - Fee Related
- 2007-02-09 MX MX2008010221A patent/MX2008010221A/es active IP Right Grant
- 2007-02-09 KR KR1020087022059A patent/KR101393652B1/ko active IP Right Grant
- 2007-02-09 BR BRPI0707616-9A patent/BRPI0707616A2/pt not_active Application Discontinuation
- 2007-02-09 AR ARP070100553A patent/AR060103A1/es not_active Application Discontinuation
- 2007-02-09 EP EP07750332.4A patent/EP1993357B1/en not_active Not-in-force
- 2007-02-09 CN CNA2007800128179A patent/CN101420850A/zh active Pending
- 2007-02-09 CA CA2638914A patent/CA2638914C/en active Active
- 2007-02-09 RU RU2008136208/15A patent/RU2008136208A/ru not_active Application Discontinuation
- 2007-02-09 US US11/673,342 patent/US9265811B2/en not_active Expired - Fee Related
- 2007-02-09 TW TW096104742A patent/TWI478721B/zh not_active IP Right Cessation
- 2007-02-09 DK DK07750332.4T patent/DK1993357T3/da active
- 2007-02-09 DK DK14150323.5T patent/DK2777695T3/da active
- 2007-02-09 ES ES07750332.4T patent/ES2459018T3/es active Active
- 2007-02-09 WO PCT/US2007/003486 patent/WO2007095092A2/en active Search and Examination
- 2007-02-09 AU AU2007215304A patent/AU2007215304B2/en not_active Ceased
- 2007-02-09 EP EP14150323.5A patent/EP2777695B1/en not_active Not-in-force
- 2007-02-09 ES ES14150323T patent/ES2700278T3/es active Active
- 2007-02-09 CN CN2013101516785A patent/CN103301070A/zh active Pending
-
2008
- 2008-08-10 IL IL193344A patent/IL193344A/en active IP Right Grant
-
2009
- 2009-05-26 HK HK09104807.6A patent/HK1126088A1/xx not_active IP Right Cessation
- 2009-11-11 US US12/616,638 patent/US8168594B2/en not_active Expired - Fee Related
-
2012
- 2012-04-18 US US13/449,819 patent/US9241969B2/en active Active
- 2012-09-26 PH PH12012501912A patent/PH12012501912B1/en unknown
-
2013
- 2013-09-17 IL IL228532A patent/IL228532A0/en active IP Right Revival
-
2015
- 2015-02-24 US US14/630,297 patent/US20150164978A1/en not_active Abandoned
- 2015-03-16 HK HK15102682.2A patent/HK1202072A1/xx not_active IP Right Cessation
-
2021
- 2021-02-01 US US17/163,942 patent/US20210154260A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1993357T3 (da) | Formuleringer af en tight junction effektor | |
NO2022040I1 (no) | pembrolizumab - forlenget SPC | |
NL350090I2 (nl) | flupyradifurone | |
FR2907877B1 (fr) | Jonction tubulaire | |
ITMI20062368A1 (it) | Composizioni erbicide | |
ATE554130T1 (de) | Lichtvernetzbare polyolefinzusammensetzungen | |
BRPI0811926A2 (pt) | Composições herbicidas | |
DK1981859T3 (da) | Fremstilling af delmopinol | |
FR2913672B1 (fr) | Joint thermoscellable | |
ITRM20060613A1 (it) | Treppiede perfezionato | |
BRPI0814188A2 (pt) | Formulações | |
UY3660Q (es) | Camara | |
DE602008001144D1 (de) | Kogenerationssystem | |
DK2111555T3 (da) | Diagnosticering af præeklampsi | |
DK2117732T3 (da) | Frembringelse af partier | |
DK2097068T3 (da) | Formuleringer af peg-interferon-alpha-konjugater | |
BRPI0815652A2 (pt) | Composições herbicidas | |
DE602007012490D1 (de) | Herbizidzusammensetzung | |
DK2229062T3 (da) | Fremgangsmåde til fremstillingen af et hydrolysat | |
FR2907178B1 (fr) | Joint homocinetique | |
DE602007013423D1 (de) | Verbesserte bemalbare thermoplastische zusammensetzungen | |
UY3657Q (es) | Cámara | |
UY3659Q (es) | Camara | |
FR2897662B1 (fr) | Joint homocinetique | |
UY3658Q (es) | Camara |